Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

66.30EUR
9:55am EDT
Change (% chg)

€0.12 (+0.18%)
Prev Close
€66.18
Open
€66.19
Day's High
€66.46
Day's Low
€65.94
Volume
769,856
Avg. Vol
2,879,050
52-wk High
€89.19
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.90
Market Cap(Mil.): €82,982.83
Shares Outstanding(Mil.): 1,248.99
Dividend: 3.03
Yield (%): 4.58

Financials

  SASY.PA Industry Sector
P/E (TTM): 17.66 28.56 32.59
EPS (TTM): 3.75 -- --
ROI: -- 13.05 12.60
ROE: -- 14.79 14.49

BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes

* FDA TO REVIEW ZYNQUISTA™ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES

8:56am EDT

RPT-EXCLUSIVE-CVC puts $9 bln Recordati bid on hold as political uncertainty weighs -sources

* Talks between CVC and Recordati started in late 2017 -sources

May 17 2018

UPDATE 1-EXCLUSIVE-CVC puts $9 bln Recordati bid on hold as political uncertainty weighs -sources

* Talks between CVC and Recordati started in late 2017 -sources

May 17 2018

EXCLUSIVE-CVC puts $9 bln Recordati bid on hold as political uncertainty weighs -sources

* Talks between CVC and Recordati started in late 2017 -sources

May 17 2018

BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)

* Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

May 16 2018

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

May 01 2018

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

May 01 2018

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

May 01 2018

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

May 01 2018

BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* REG-SANOFI: FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 30 2018

Earnings vs. Estimates